The puff and hype in all of this is mesmerizing!
>>>>>>>>>>>>>>>>. ‘Mesmerizing’ is a bit over the top. However, if the company needed a boost then this is one of the best it could have ever expected. It may not be obvious now, but IMO this is a totally new ball game!
Have any of you looked at the kindergarten strategy doc released by management?
>>>>>>>>>>>>>>>>>>>>>>>I agree, pretty basic stuff…. pre-announcement. Are you of the opinion that the pre-announcement management will continue in the same vain in the future?...... I think not.
None of the fundamentals work here. No growth. No strategy.
>>>>>>>>>>>>>>>>>. Again, are referring to pre or post announcement?
If “pre”, I agree………….. if ‘post’ then you have absolutely no basis for this comment whatsoever.
Seeing you are no longer holding this stock, it really shouldn’t concern you anyway.
An announcement that will return no income for a year or two. Hype.
>>>>>>>>>>>>>>>. On what grounds do you make such a bold statement? Even a hard core pessimist would agree that at least this gives the company a 2nd chance. It was clearly going broke and probably would have by years end without an intervening Wolf. You clearly have no investments in Cannabis stocks at all, so I understand your position of simply not knowing.
That's what is at play here.
>>>>>>>>>>>>>>>>> you have no basis for that comment.
It's not like me to bag a stock, but this recent rise is unlikely to be sustainable unless something significantly changes at the company.
>>>>>>>>>>>>>>>>>>>>>>>>>> you simply haven’t come to grasp the positive impact of what Ross Smith will bring to this company. The significant changes are now set to happen.
I'll stay quiet from here on in as I know what it's like having constant naysayers in a stocks thread. I am not your classic troll.
But when my prediction comes true - "I'll be back. Hasta la vista baby!"
>>>>>>>>>>>>>>>>>>>>>>>>> ….. and if your prediction does not come true?
By the way, I am not aware of any current cannabis company (listed or unlisted) in Aust or NZ that has board members from both the medical and pharmaceutical fraternity. Medicann does…………..
“The Board of MediCann includes Dr Franz Strydon, a noted New Zealand medical practitioner and skin cancer specialist, as chairman, and Elizabeth Plant, a noted pharmacist in New Zealand, the former President of the NZ Pharmaceutical Society for 5 years
(2008-2013) and a ministerial appointee to the NZ National Health IT Board (NHITB) for eight years (2008-2016). The MediCann Managing Director is Brendon Ogilvy, also a New Zealand citizen, and an experienced IT and sales executive with extensive international management experience.”
If you are not clear on the direction of the company now, read the recent JHL:ASX release. If you are unclear where the share price is due to be driven by Smith over the coming months, then read through both Schedules 1 & 2. In particular Schedule 2 (iv) where triggers for Performance Rights will automatically vest following .....“volume weighted average market price of over 14 consecutive ASX trading days of 30c per JHL share or more; and…..”
"The Wolf" will be going all out for the ‘or more’ option, I am sure!
